This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 216-222, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo

Johan Neyts,* Graciela Andrei, and Erik De Clercq

Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

Received 30 June 1997/Returned for modification 16 September 1997/Accepted 5 November 1997

The immunosuppressive agent mycophenolate mofetil (MMF) has been approved for use in kidney transplant recipients and may thus be used concomitantly for the treatment of intercurrent herpesvirus infections with drugs such as acyclovir (ACV), ganciclovir (GCV), and penciclovir (PCV). We found that MMF and its parent compound mycophenolic acid (at concentrations that are attainable in plasma) strongly potentiate the antiherpesvirus (herpes simplex virus [HSV] type 1 [HSV-1], HSV-2, thymidine kinase-deficient [TK-] HSV-1, both wild-type and TK- varicella-zoster virus, and human cytomegalovirus) activities of ACV, PCV, and GCV (up to 350-fold increases in their activities). The mechanism of potentiation was found to reside in the depletion of endogenous dGTP pools, which favored the inhibitory effect of the triphosphate of ACV, GCV, or PCV on the viral DNA polymerase. The combination of topically applied 5% MMF with 0.1% ACV strongly protected against HSV-1-induced cutaneous lesions in hairless mice, whereas therapy with either compound used singly had no protective effect. Interestingly, the combination of topically applied 5% MMF with 5% ACV was also highly effective in protecting against TK- HSV-2-induced cutaneous lesions (that were refractory to ACV treatment) in athymic nude mice. Topical therapy with MMF was very well tolerated, and no signs of irritation were observed. When given perorally at 200 mg/kg of body weight/day, MMF potentiated to some extent the growth retardation induced by GCV in young NMRI mice. These observations may have clinical implications (i) for those transplant recipients who receive both MMF and either ACV, GCV, or PCV and (ii) for the treatment of ACV-resistant mucocutaneous HSV infections.

* Corresponding author. Mailing address: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32-16-33.73.53. Fax: 32-16-33.73.40. E-mail: Johan.Neyts{at}rega.kuleuven.ac.be.

Antimicrobial Agents and Chemotherapy, February 1998, p. 216-222, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gibson, W T, Hayden, M R (2006). Mycophenolate mofetil and animal models. Lupus 15: 27-34 [Abstract]  
  • Zierhut, M, Stubiger, N, Siepmann, K, Deuter, C M. (2005). MMF and eye disease. Lupus 14: s50-s54 [Abstract]  
  • Leyssen, P., Balzarini, J., De Clercq, E., Neyts, J. (2005). The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase. J. Virol. 79: 1943-1947 [Abstract] [Full Text]  
  • Zierhut, M., Stubiger, N., Siepmann, K., Deuter, C. (2005). MMF and eye disease. Lupus 14: s50-s54 [Abstract]  
  • Borroto-Esoda, K., Myrick, F., Feng, J., Jeffrey, J., Furman, P. (2004). In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 4387-4394 [Abstract] [Full Text]  
  • Hermann, L. L., Coombs, K. M. (2004). Inhibition of Reovirus by Mycophenolic Acid Is Associated with the M1 Genome Segment. J. Virol. 78: 6171-6179 [Abstract] [Full Text]  
  • GIRAL, M., NGUYEN, J. M., DAGUIN, P., HOURMANT, M., CANTAROVICH, D., DANTAL, J., BLANCHO, G., JOSIEN, R., ANCELET, D., SOULILLOU, J. P. (2001). Mycophenolate Mofetil Does Not Modify the Incidence of Cytomegalovirus (CMV) Disease after Kidney Transplantation but Prevents CMV-Induced Chronic Graft Dysfunction. J. Am. Soc. Nephrol. 12: 1758-1763 [Abstract] [Full Text]  
  • Grundmann-Kollmann, M., Podda, M., Ochsendorf, F., Boehncke, W.-H., Kaufmann, R., Zollner, T. M. (2001). Mycophenolate Mofetil Is Effective in the Treatment of Atopic Dermatitis. Arch Dermatol 137: 870-873 [Abstract] [Full Text]  
  • De Clercq, E. (2001). Molecular Targets for Antiviral Agents. J. Pharmacol. Exp. Ther. 297: 1-10 [Abstract] [Full Text]  
  • Markland, W., McQuaid, T. J., Jain, J., Kwong, A. D. (2000). Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon. Antimicrob. Agents Chemother. 44: 859-866 [Abstract] [Full Text]  
  • Sia, I. G., Patel, R. (2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. Clin. Microbiol. Rev. 13: 83-121 [Abstract] [Full Text]  
  • Neyts, J., De Clercq, E. (1999). Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs. Antimicrob. Agents Chemother. 43: 2885-2892 [Abstract] [Full Text]  
  • Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., Crisp, A., Lee, I. C., The International Valacyclovir Cytomegalovirus Pro, (1999). Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation. NEJM 340: 1462-1470 [Abstract] [Full Text]  
  • Neyts, J., Andrei, G., De Clercq, E. (1998). The Antiherpesvirus Activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil. Antimicrob. Agents Chemother. 42: 3285-3289 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»